it remains unlicensed in the UK and EU
BMJ Journals
Two products labelled BPC-157 may appear identical on the surface while being produced under completely different conditions
The familiar figures are a well-used convention rather than a precisely proven timetable
Some of those risks include Hematoma, scar deformities, skin necrosis, infection, bleeding, and eye injury
If the patient is suspected to be sensitive to cobalt or other components of cobalamin, an intradermal test dose is recommended.[12][15] Several laboratory tests should be performed prior to treatment with cyanocobalamin, including serum vitamin B12, folate, iron, hematocrit, and reticulocyte count